CLINICAL GUIDELINE FOR ALCOHOL DETOXIFICATION AND ADMINISTRATION OF CHLORDIAZEPOXIDE AT RCHT 1. Aim/Purpose of this Guideline

Similar documents
REFERENCE. Admit to: Program/Service: Diagnosis: Droplet/ Contact Airborne/ Contact

CLINICAL GUIDELINE FOR THE MANAGEMENT OF OPIATE DEPENDENT PATIENTS AT RCHT 1. Aim/Purpose of this Guideline

Alcohol Withdrawal. Mild Withdrawal Moderate Withdrawal Severe Withdrawal. Mild anxiety Malaise Marked anxiety

CLINICAL GUIDELINE FOR THE MANAGEMENT OF HYPERGLYCAEMIA IN ADULTS WITH ACUTE CORONARY SYNDROME

This guideline is for the management of Adult patients with Diabetes Mellitus using insulin pump therapy during admission to hospital

Version 2 This guideline describes how to manage patients who are showing signs and symptoms of alcohol withdrawal and Wernicke s Encephalopathy.

Supported Alcohol Withdrawal Treatment Information

Assessment and management of alcohol dependence and withdrawal in the acute hospital

ALCOHOL DETOXIFICATION (IN-PATIENTS) PRESCRIBING GUIDELINE

SEPSIS IN INFANTS AND CHILDREN- CLINICAL GUIDELINE 1. Aim/Purpose of this Guideline

CLINICAL GUIDELINE HOW TO PERFORM A VENESECTION, DETAILING VEIN SELECTION AND PATIENT CARE 1. Aim/Purpose of this Guideline

CLINICAL GUIDELINE FOR THE USE OF INTRAVENOUS SLIDING SCALE REGIMEN FOR ADULTS 1. Aim/Purpose of this Guideline

Alcohol Liaison Service. Alcohol Withdrawal. Information

Glasgow Assessment and Management of Alcohol

Occupational Therapy Service in the Emergency Department at Royal Cornwall Hospital V1.0

2.1 When a breastfeeding woman is admitted to hospital, the support she needs depends on the nature of her illness and the treatment needed

The Use of Electronic signatures for Prescribing Chemotherapy and data entries on the Aria MedOncology system V3.0

THE BASICS. Community Based Medically Assisted Alcohol Withdrawal. World Health Organisation The Issues 5/18/2011. RCGP Conference May 2011

Title Alcohol Withdrawal Management Guidelines

Managing Patients with Alcohol Withdrawal

MANAGEMENT OF DIRECT ANTIGLOBULIN TEST (DAT) POSITIVE INFANTS NEONATAL CLINICAL GUIDELINE

Clinical Guideline For The Use of Rectus Sheath Catheters For The Management of Pain Following Laparotomy. 1. Aim/Purpose of this Guideline

2.6.4 Medication for withdrawal syndrome

Phenobarbital in Severe Alcohol Withdrawal Syndrome. Jordan Rowe Pharm.D. Candidate UAMS College of Pharmacy

Diagnostic Testing Procedures for Ophthalmic Science

GUIDELINES FOR COMMUNITY ALCOHOL DETOXIFICATION IN SHARED CARE

Procedure for Non-Medical Staff who wish to Request MRI, Ultrasound and Imaging Examinations under IR(ME)R

How To Treat An Alcoholic Patient

General PROVIDER INITIALS: PHYSICIAN ORDERS

2.1. Applicable areas: Royal Cornwall Hospitals Trust; Neonatal Unit and Delivery Suite

Accounts Receivable - Guidance to staff responsible for the collection of income following the supply of goods or services V4.0

Alcohol Dependence Inpatient management of Alcohol Withdrawal

CLINICAL GUIDELINE FOR VAGINAL BIRTH AFTER CAESAREAN SECTION (VBAC)

Live Person Simulation Scenario Psychiatric and Mental Health Nursing (Sandra)

CLINICAL IMAGING REFERRAL PROTOCOL FOR REGISTERED HEALTHCARE PRACTITIONERS EMPLOYED WITHIN MINOR INJURY UNITS IN CORNWALL

STANDARD OPERATING PROCEDURE. Administration of High Dose Muscular Vitamin Supplements for Undergoing Alcohol

New York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery

MANAGEMENT OF ALCOHOL PROBLEMS ON PSYCHIATRIC WARDS

Does This Hospital Serve Cocktails? Alcohol Withdrawal: A Nursing Perspective. Written and presented by: Susan Laffan, RN, CCHP-RN, CCHP-A

Alcohol Withdrawal Syndrome & CIWA Assessment

Symptom-Triggered Alcohol Detoxification: A Guideline for use in the Clinical Decisions Unit of the Emergency Department.

SCOTTISH PRISON SERVICE DRUG MISUSE AND DEPENDENCE OPERATIONAL GUIDANCE

PREGNANCY OF UNKNOWN LOCATION (PUL) - CLINICAL GUIDELINE 1. Aim/Purpose of this Guideline

CLINICAL GUIDELINE FOR CHANGING A CATHETER EXIT SITE DRESSING (I.E. MIDLINE/ CVC/ PICC/ HICKMAN) Summary. Start

Trust Clinical Policy. Directorate/Department/Specialist Group Emergency Department, Medical Admissions Unit and All wards and Departments

Alcohol Withdrawal in the AMU. Dr Ewan Forrest Glasgow Royal Infirmary

STROKE AND TIA MULTIDISCIPLINARY CARE PATHWAY 6 th Edition Cornwall Stroke Service (Royal Cornwall Hospital Trust Facing)

SPECIFICATION FOR THE LOCAL COMMISSIONED SERVICE FOR THE MANAGEMENT ALCOHOL MISUSE

CLINICAL GUIDELINE FOR MANAGEMENT OF NEUTROPENIC SEPSIS IN CANCER PATIENTS 1. Aim/Purpose of this Guideline

Guidance on Leases and other Agreements V4.0

Management of benzodiazepine misuse

Phenobarbital Use as Adjunct to Benzodiazepines in the Treatment of Severe Alcohol Withdrawal Syndrome

Review Group: Mental Health Operational Medicines Management Group. Signature Signature Signature. Review Date: December 2014

Alcohol information. A standard drink contains about 10g of alcohol takes a healthy liver about 1 hour to remove alcohol from the body.

1. According to recent US national estimates, which of the following substances is associated

OXYGEN THERAPY AND SATURATION MONITORING OF THE NEONATE - CLINICAL GUIDELINE

Symptom Based Alcohol Withdrawal Treatment

Adjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.

CLINICAL GUIDELINE FOR ADVANCED NURSE PRACTITIONER HEPATOLOGY (GASTROENTEROLOGY) 1. Aim/Purpose of this Guideline:

Grievance and Disputes Policy and Procedure. Document Title. Date Issued/Approved: 10 August Date Valid From: 21 December 2015

This controlled document shall not be copied in part or whole without the express permission of the author or the author s representative.

Alcohol and nicotine are widely abused substances and are often used together One study showed that 15% of patients visiting a primary care practice

GP Drug & Alcohol Supplement No.7 May 1997

Guidance for the Detoxification of Alcohol Dependent Patients in Community or Outpatient Settings

Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services

ALCOHOL ASSESSMENT AND DETOXIFICATION POLICY FOR INPATIENTS

CALDERDALE ALCOHOL TEAM & Calderdale Substance Misuse Service COMMUNITY ALCOHOL DETOXIFICATION GUIDELINE

Pharmacological Management of Acute Alcohol Withdrawal and Relapse Prevention in alcohol Use disorders in the Community

Alcohol. Problems with drinking alcohol

Alcohol Withdrawal. Introduction. Blood Alcohol Concentration. DSM-IV Criteria/Alcohol Abuse. Pharmacologic Effects of Alcohol

DRUG AND ALCOHOL DETOXIFICATION: A GUIDE TO OUR SERVICES

YCN Head & Neck NSSG Alcohol Assessment and Detoxification Management Guidelines

Alcohol Withdrawal Recognition and Treatment

NewYork-Presbyterian Hospital Sites: All Centers Medication Use Manual: Guideline Page 1 of 12

Alcohol Withdrawal Syndromes

Under Review. Policy for Self Administration of medicines (SAM) by Competent Patients. Document Title. Date Issued/Approved: 18 th October 2013

CLINICAL GUIDELINE FOR THE EMERGENCY DEFILL OF AN ADJUSTABLE GASTRIC BAND

Trust Guideline for the Management of: Acute Alcohol withdrawal (excluding pregnancy)

ALCOHOL ASSESSMENT AND DETOXIFICATION POLICY FOR INPATIENTS

University of Michigan Alcohol Withdrawal Guidelines Overview

Outpatient Treatment of Alcohol Withdrawal. Daniel Duhigg, DO, MBA

How To Work With A Comorbidity

EMS Branch / Office of the Medical Director. Active Seziures (d) Yes Yes Yes Yes. Yes Yes No No. Agitation (f) No Yes Yes No.

SUBSTANCE USE DISORDER SOCIAL DETOXIFICATION SERVICES [ASAM LEVEL III.2-D]

COMMUNITY BUPRENORPHINE PRESCRIBING IN OPIATE DEPENDENCE

CLINICAL GUIDELINE FOR THE MANAGEMENT OF HIGH BLOOD GLUCOSE LEVELS AND SICK DAYS ON AN INSULIN PUMP. 1. Aim/Purpose of this Guideline

X10 DETOXIFICATION PROTOCOLS AND WITHDRAWAL SCALES

Guidelines for Titration onto Buprenorphine in Opioid Dependence

Substance Use Learning Event Nov 3, 2015 Bill Bullock MD, CCFP

BCUHB SUBSTANCE MISUSE SERVICE INPATIENT DETOXIFICATION PRESCRIBING GUIDELINES

INTOXICATED PATIENTS AND DETOXIFICATION

Lorraine Wilson, 74 years of age, is admitted. Alcohol Withdrawal. During Hospitalization. Early recognition and consistent intervention are critical.

How To Know If You Should Be Treated

Alcohol use disorders: sample chlordiazepoxide dosing regimens for use in managing alcohol withdrawal

PHARMACISTS AMENDMENTS TO PRESCRIPTIONS

The Pharmacological Management of Cancer Pain in Adults. Clinical Audit Tool

Maintenance of abstinence in alcohol dependence

CLINICAL GUIDELINE FOR MANAGEMENTS OF PATIENTS TAKING ANTICOAGULANTS IN ENDOSCOPY 1. Aim/Purpose of this Guideline

Alcohol Dependence and Motivational Interviewing

The reaction is termed anaphylaxis if there are life-threatening features such as respiratory difficulties and/or hypotension.

Transcription:

CLINICAL GUIDELINE FOR ALCOHOL DETOXIFICATION AND ADMINISTRATION OF CHLORDIAZEPOXIDE AT RCHT 1. Aim/Purpose of this Guideline 1.1. Guidance for all clinical staff at RCHT for the treatment of alcohol withdrawal and administration of chlordiazepoxide. 2. The Guidance Page 1 of 16

ALCOHOL DETOXIFICATION AND CHLORDIAZEPOXIDE (CDZ) ADMINISTRATION GUIDELINES For first 24 hours only: Prescribe CDZ 20-50mg prn to be administered as per CIWA score (alcohol withdrawal scale). Maximum CDZ 250mg in 24 hours. Senior medical staff should be consulted if this limit is to be exceeded. Do not prescribe Phenytoin for alcohol withdrawal seizures. Do not prescribe any regular CDZ or other regular sedatives for first 24 hours Commence Pabrinex 1&2 (one pair) IV daily for 3 days ASAP. Use IM Pabrinex 1 pair OD if unable to gain IV access. Note Alcohol dependant hypoglycaemic patients should be given Pabrinex with or prior to IV glucose If patient has any one of following symptoms: Acute confusion, Decreased consciousness level, Memory disturbance, Ataxia/unsteadiness, Opthalmoplegia, Nystagmus, unexplained hypotension with hypothermia commence Pabrinex 3 pairs TDS for 3 days then 1 pair daily for 3 days or until clinical improvement stops. Use IM Pabrinex 1 pair BD if no IV access. Check Magnesium levels (if low patient will not uptake Pabrinex) If problems of disturbed behaviour occur prescribe prn lorazepam 1-2mg oral/im (tablets may be administered sublingually if IM preparation unavailable) (maximum 4mg in 24 hours) in addition to CDZ. Lorazepam 1mg = CDZ 30mg therefore nurses and doctors should add this to CDZ given to ensure maximum CDZ 250mg in 24 hours is not exceeded. If patient requires IV sedation discuss with Critical Care On Day 2 calculate the total CDZ dose given in initial 24 hours. Divide this dose (including equivalent CDZ dose of any lorazepam given) into equal qds doses and prescribe for Day 2 of detoxification regimen. Reduce CDZ by approx 20% or10mg QDS daily after Day 2 Prn CDZ/sedation should not be required from Day 2 onwards, however if withdrawal symptoms worsen recommence CIWA scoring and prn administration. Contact RCHT Alcohol Liaison Team 8am - 4pm 7 days a week for Brief Intervention and referral to Community Alcohol Services. For advice regarding management of detoxification/wernickes Encephalopathy contact Psychiatric Liaison via bleep through Bodmin Switchboard on ext: 1300 8am - 8pm 7 days a week. Please read accompanying guidelines for CIWA scoring information and further alcohol detoxification care. Page 2 of 16

CHART OF THE CLINICAL INSTITUTE WITHDRAWAL ASSESSMENT FOR ALCOHOL (CIWA) SCORE & CHLORDIAZEPOXIDE ADMINISTERED DURING THE FIRST 24 HOURS OF THE ALCOHOL DETOXIFICATION REGIME Name of Patient or affix patient label Address.......hrs Date of birth CR Number.. Day/Date/Time Commenced: day./ /.. Consultant The administration of chlordiazepoxide & continuing monitoring for the first 24hrs should follow this table Maximum 250 mg chlordiazepoxide in 24 hours. Lorazepam 1mg Chlordiazepoxide 30mg CIWA Score (see reverse) Frequency of CIWA observations Before first dose of chlordiazepoxide is required After first and subsequent doses of chlordiazepoxide Administration of chlordiazepoxide 0-10 Hourly Two hourly Nil 11 or greater Two hourly 20 50 mg DATE & TIME CIWA SCORE CHLORDIAZEPOXIDE DOSE (INCLUDE LORAZEPAM) Calculate total chlordiazepoxide dose administered in the first 24 hours. Divide into equal QDS doses. Prescribe on day two of detoxification regime. From day three reduce chlordiazepoxide by approximately 20% daily over five to seven days then stop. PRN chlordiazepoxide or other Page 3 of 16

sedative should not usually be required from day two onwards.see guidelines for vitamin supplementation Page 4 of 16

Clinical Institute Withdrawal Assessment for Alcohol (CIWA-AR) (Sullivan et al., 1989) Nausea and Vomiting Ask do you feel sick to your stomach? Have you vomited? Observation 0 No nausea. 1 Mild nausea with no vomiting. 2 3 4 Intermittent nausea with dry heaves. 5 6 7 Constant nausea, frequent dry heaves and vomiting. Tremor arms extended and fingers spread apart Observation 0 No tremor. 1 Not visible, but can be felt fingertip to fingertip. 2 3 4 Moderate, with patient s arms extended. 5 6 7 Severe, even with arms not extended. Paroxysmal Sweats Observation 0 No sweat visible. 1 Barely perceptible sweating, palms moist. 2 3 4 Beads of sweat obvious on forehead. 5 6 7 Equivalent to acute panic states as seen in severe delirium or acute schizophrenic reactions. Anxiety Ask do you feel nervous? Observation Tactile Disturbances Ask have you any itching, pins and needles, any burning or numbness or do you feel bugs crawling under your skin? 0 None. 1 Very mild itching, pins ad needles, burning or numbness. 2 Mild itching, pins and needles, burning or numbness. 3 Moderate itching, pins and needles, burning or numbness. 4 Moderately severe hallucinations. 5 Severe hallucinations. 6 Extremely severe hallucinations. 7 Continuous hallucinations. Auditory Disturbances Ask are you more aware of sounds around you? Are they harsh? Do they frighten you? 0 Not present. 1 Very mild sensitivity. 2 Mild harshness or ability to frighten. 3 Moderate harshness or ability to frighten. 4 Moderately severe hallucinations. 5 Severe hallucinations. 6 Extremely severe hallucinations. 7 Continuous hallucinations. Visual Disturbances Ask does the light appear to be too bright? Is its colour different? Does it hurt your eyes? Are you seeing anything that is disturbing to you? Are you seeing things that you know are not there? Observation 0 Not present. 1 Very mild sensitivity. 2 Mild sensitivity. 3 Moderate sensitivity. 4 Moderately severe hallucinations. 5 Severe hallucinations. 6 Extremely severe hallucinations. 7 Continuous hallucinations. Headache, Fullness in Head Ask does your head feel different? Does it feel like there is a band around your head? Do not rate for dizziness or light-headedness. Otherwise rate severity. 0 No anxiety. 1 Mildly anxious. 2 3 4 Moderately anxious or guarded so anxiety is inferred. 5 6 7 Equivalent to acute panic states as seen in severe delirium or acute schizophrenic reactions. Agitation Observation 0 Normal activity. 1 Somewhat more than normal activity. 2 3 4 Moderately fidgety and restless. 5 6 7 Paces back and forth during most of the interview or constantly thrashes out. Page 5 of 16 0 Not present. 1 Very mild. 2 Mild. 3 Moderate. 4 Moderately severe. 5 Severe. 6 Very severe. 7 Extremely severe. Orientation and Clouding of Sensorium Ask what day is this? Where are you? Who am I? 0 Orientated and can do serial additions. 1 Cannot do serial additions or is uncertain about date. 2 Disorientated for date by no more than 2 calendar days. 3 Disorientated for date by more than 2 calendar days. 4 Disorientated for place and/or person.

Ongoing Vitamin Supplementation Pabrinex 1&2 (1pair) IV daily for 3 days (Use IM Pabrinex if no IV access) Thiamine PO 300mg tablets od or 100mg tds (To be given alongside Pabrinex) Vitamin B co strong PO 2 tablets od (To be given alongside Pabrinex) Monitoring CIWA score for 1 st 24 hours BP & TPR with CIWA for 1 st 24 hours then BD for days 2-6 GCS in patients with reduced GCS Presentations of note Head Injury In most cases patients that are admitted with a head injury can be managed with the above guidelines but if you are concerned about the effect of benzodiazepines on a serious head injury then seek senior advice or advice from specialist neurosurgical team at Derriford. Alcohol withdrawal cannot be ignored in these patients. Impaired Hepatic Function If you are concerned about the effect of chlordiazepoxide in a patient with acute hepatic impairment change to Lorazepam oral as this is less likely to accumulate and cause encephalopathy and seek advice from the Gastroenterology Team. Opiate Dependant and Alcohol Dependant Patients If the patient has a community Opiate prescription then this should be confirmed and continued and assessment for alcohol withdrawal symptoms with benzodiazepines titrated on top of Opiate prescription. If the patient is dependant on street opiates then alcohol withdrawal symptoms should take priority and assess using CIWA but do not give opiates to treat opiate withdrawal symptoms. Page 6 of 16

GUIDELINES.FOR TREATMENT OF ALCOHOL WITHDRAWAL The approach advocated here is to prescribe chlordiazepoxide according to a flexible regimen over the first 24hours, with dosage titrated against the rated severity of withdrawal symptoms. This is followed by a fixed 5-7 day reducing regimen, based upon the dosage requirement estimated during the first 24 hours. The intention of the flexible protocol for the first 24 hours is to titrate the dosage of chlordiazepoxide against the severity of alcohol withdrawal symptoms. It is necessary to avoid under-treatment (associated with patient discomfort and a higher incidence of complications such as fits or DTs) or over-treatment (associated with excessive sedation and risk of toxicity/interaction with alcohol consumed prior to admission). Important points to note when evaluating the patient Drinking history describe amount and type of alcohol and calculate units. Past history of alcohol withdrawal Complications associated with previous withdrawal episodes such as seizures or delirium. Time elapsed since last alcoholic drink This information can then be used to anticipate the severity, timing and possible complications of withdrawal symptoms. Advice can be given to nursing staff on patient management and dose ranges to be used. Medication such as Diazepam PR can be prescribed if patients are at risk of withdrawal seizure. Prescribing of chlordiazepoxide First 24 hours (day 1) Dose range A flexible dose range for the first 24 hours only should be prescribed and administered as per the CIWA score. Chlordiazepoxide should be administered when withdrawal symptoms are considered significant (usually CIWA score more than 11). See enclosed table and administration chart. A dose range of 20-50mg will cover almost all circumstances. Delirium & Disturbed Behaviuor Consider use of Lorazepam 1 2 mg Oral / IM for disturbed behaviour (due to the shortage of parental Lorazepam, consider Clonazepam IV, Lorazepam 1mg = Clonazepam 2mg) Page 7 of 16

Maximum dose in 24 hours The maximum cumulative dose which may be given during the first 24 hours must be stated. This should usually be a maximum of 250mg chlordiazepoxide unless discussed with Consultant, Senior Registrar or Psychiatric Liaison. Lorazepam 1 mg = Chlordiazepoxide 30 mg and should therefore be included in this maximum dose. Days 2-5 The total cumulative dose administered during the initial 24 hrs is the baseline dose. This baseline dose should be divided into equal QDS doses and prescribed as Day 2 of the detoxification regime. Then reduce the doses by approximately 20% or 10mg QDS daily over the following 5-7 days. Withdrawal Seizures Patient s at risk of seizures should be prescribed Diazepam 5mg pr prn. Do not prescribe Phenytoin for alcohol withdrawal seizures Intravenous sedation Intravenous sedation should only be given if agreed by a medical consultant and if there is one to one nursing available, in general this means the patient should be cared for on Critical Care. Vitamin Supplementation Prevention and Treatment of Wernicke s encephalopathy Commence Pabrinex 1&2 (1 pair) iv daily for 3 days ASAP (usually given with 100mls 5% glucose) as slow infusion. Patients with any one of the following symptoms: Acute confusion, Decreased conscious level, Memory Disturbance, Ataxia/unsteadiness, opthalmoplegia, nystagmus, Unexplained hypotension with hypothermia may have Wernicke s encephalopathy (WE) or if patients are at high risk of developing WE (Homeless, Malnourished, IV drug use or previous WE) and should be prescribed Pabrinex 3 pairs TDS for 3 days followed by I pair for 3 to 5 days or until clinical improvement stops. Note alcohol dependent hypoglycaemic patients should be given Pabrinex with or prior to the administration of IV glucose to prevent precipitating Wernicke s encephalopthy.. Thiamine 100mg tablet tds orally or 300mg od Vitamin B Co Strong two tablets tds orally Monitor CIWA Score, Pulse, Blood Pressure, Respiration, Temperature &GCS in patients with a reduced GCS Page 8 of 16

Use of CIWA rating scale The CIWA scale is a guide to assessing the severity of withdrawal symptoms. If the patient is asleep the CIWA score is nil. It is not always necessary to ask the patient all of the questions listed each time a CIWA assessment is completed. The usual medical or nursing observations of a patient s emotional or mental state will often be sufficient to rate symptoms without asking all the questions suggested on the rating scale. The CIWA score is a guide to the amount of sedative to be given. Factors such as the age, weight and physical condition of the patient should also influence the dose of chlordiazepoxide given Maintain a safe environment Sedated patients are at risk of dehydration. Observations can be recorded twice daily from days 2-6 Consider one to one nursing for disturbed patients, refer to RCHT Safe and Supportive Observation Policy Contact Contact RCHT Alcohol Liaison Team 8am - 4pm 7 days a week for Brief Intervention and referral to Community Alcohol Services. For advice regarding management of detoxification/wernickes Encephalopathy contact Psychiatric Liaison via bleep through Bodmin Switchboard on ext: 1300 8am - 8pm 7 days a week. Please read accompanying guidelines for CIWA scoring information and further alcohol detoxification care. Discharge Patients who discharge against medical advice should not be prescribed benzodiazepines as TTO s. Planned discharges should usually have completed the detoxification regimen prior to discharge. Page 9 of 16

PABRINEX ADMINISTRATION YES DOES THE PATIENT HAVE SYMPTOMS OF WERNICKES? (PLEASE REFER TO ALCOHOL DETOXIFICATION GUIDELINES) NO ARE YOU ABLE TO OBTAIN IV ACCESS? YES YES NO PX IV PABRINEX 2 to 3 PAIRS TDS FOR 3-5 DAYS NO PX IV PABRINEX 1 PAIR OD FOR 3 DAYS PX IM (HIGH POTENCY) PABRINEX 2 PAIRS TDS FOR 2 DAYS; IF NO RESPENSE, DISCONTINUE: IF SYMPTOMS RESOLVE AFTER 2 DAYS GIVE 1 PAIR OD FOR 5 DAYS OR FOR AS LONG AS IMPROVEMENT CONTINUES PX IM (HIGH POTENCY) PABRINEX 1 PAIR OD FOR 3 DAYS PLEASE NOTE WHEN GIVING IM PABRINEX: DUE TO THE AMOUNT OF FLUID IN ONE DOSE (7MLS) IT IS BEST PRACTICE TO GIVE IN TWO INJECTION SITES. IE; MIX BOTH AMPULES ADMINISTER HALF, CHANGE NEEDLES AND ADMINISTER OTHER HALF IN TO A DIFFERENT SITE. Page 10 of 16

Monitoring compliance and effectiveness Element to be monitored Appropriate use of CIWA, chlordiazepoxide prescription and prescribing of Pabrinex Lead Tool Frequency Reporting arrangements Acting on recommendations and Lead(s) Change in practice and lessons to be shared Substance Misuse Liaison Nurse No specific tool will be used the Psychiatric Liaison Team to Audit Audit should be done 6 months after introduction of the guidelines The Psychiatric Liaison Team is responsible for updating and Auditing the guidelines The Psychiatric Liaison Team is responsible for updating and Auditing the guidelines Identified changes will be identified and actioned within 3 months by the Psychiatric Liaison Team following discussion with appropriate clinical ream (ie, Gastroenterology, Pharmacy) 3. Equality and Diversity 3.1. This document complies with the Royal Cornwall Hospitals NHS Trust service Equality and Diversity statement. 3.2. Equality Impact Assessment The Initial Equality Impact Assessment Screening Form is at Appendix 2. Page 11 of 16

Appendix 1. Governance Information Document Title Guidelines for Alcohol Detoxification and Chlordiazepoxide Administration at RCHT Date Issued/Approved: Date signed Date Valid From: 8 th December 2015 Date Valid To: 8 th December 2018 Directorate / Department responsible (author/owner): Contact details: 01872 253477 Medical Directorate Andy Brooking, Psychiatric Liaison Nurse (Alcohol/Delirium Lead) Brief summary of contents Suggested Keywords: Target Audience Executive Director responsible for Policy: Date revised: This document replaces (exact title of previous version): Approval route (names of committees)/consultation: Divisional Manager confirming approval processes Guidelines for the treatment of alcohol withdrawal and the administration of chlordiazepoxide Alcohol, Detoxification, Chlordiazepoxide, Delirium Tremens RCHT PCT CFT Job Title Guidelines for Alcohol Detoxification and Chlordiazepoxide Administration at RCHT Senior Medical staff and Pharmacy representative Addaction Specialist Substance Misuse Consultant Name and Post Title of additional signatories Signature of Executive Director giving approval Publication Location (refer to Policy on Policies Approvals and Ratification): Document Library Folder/Sub Folder None {Original Copy Signed} Internet & Intranet Clinical Intranet Only Links to key external standards Care Quality Commission Outcomes 4 & 9 Page 12 of 16

Related Documents: Training Need Identified? Guidelines for the correct treatment of Opiate Dependent Patients in RCHT No Version Control Table Date Version No. Summary of Changes July 2002 1 Original ratification Changes by Bob Taylor & Joanna Lawrence August 2009 2 Full review Changes made to prescribing advice for Pabrinex September 2012 3 Full review Advice not to give Phenytoin for alcohol withdrawal seizures, monitor magnesium levels and alternative medication to lorazepam for Delirium tremens December 2015 4 Full review Andy Brooking Changes made to Psychiatric Liaison hours of working All or part of this document can be released under the Freedom of Information Act 2000 This document is to be retained for 10 years from the date of expiry. This document is only valid on the day of printing Andy Brooking Andy Brooking Controlled Document This document has been created following the Royal Cornwall Hospitals NHS Trust Policy on Document Production. It should not be altered in any way without the express permission of the author or their Line Manager. Page 13 of 16

Appendix 2.Initial Equality Impact Assessment Screening Form Guidelines for Alcohol Detoxification and Chlordiazepoxide Administration at RCHT Directorate and service area: Is this a new or existing Procedure? Update of existing guidelines Name of individual completing Telephone: assessment: Andy Brooking 01872 253477 1. Policy Aim* Guidance on the treatment of Alcohol Detoxification and the Administration of chlordiazepoxide 2. Policy Objectives* Safe treatment of patients with alcohol withdrawal symptoms at RCHT 3. Policy intended Outcomes* 4. How will you measure the outcome? 5. Who is intended to benefit from the Policy? 6a. Is consultation required with the workforce, equality groups, local interest groups etc. around this policy? Safe treatment of patients with alcohol withdrawal symptoms at RCHT Audit All patients admitted to RCHT that experience alcohol withdrawal symptoms No b. If yes, have these groups been consulted? c. Please list any groups who have been consulted about this procedure. *Please see Glossary Page 14 of 16

7. The Impact Please complete the following table using ticks. You should refer to the EA guidance notes for areas of possible impact and also the Glossary if needed. Where you think that the policy could have a positive impact on any of the equality group(s) like promoting equality and equal opportunities or improving relations within equality groups, tick the Positive impact box. Where you think that the policy could have a negative impact on any of the equality group(s) i.e. it could disadvantage them, tick the Negative impact box. Where you think that the policy has no impact on any of the equality group(s) listed below i.e. it has no effect currently on equality groups, tick the No impact box. Equality Group Age Positive Impact Negative Impact No Impact Reasons for decision Disability Religion or belief Gender Transgender Pregnancy/ Maternity Race Sexual Orientation Marriage / Civil Partnership You will need to continue to a full Equality Impact Assessment if the following have been highlighted: A negative impact and No consultation (this excludes any policies which have been identified as not requiring consultation). 8. If there is no evidence that the policy promotes equality, equal opportunities or improved relations - could it be adapted so that it does? How? Full statement of commitment to policy of equal opportunities is included in the policy Please sign and date this form. Keep one copy and send a copy to Matron, Equality, Diversity and Human Rights, c/o Royal Cornwall Hospitals NHS Trust, Human Resources Department, Chyvean House, Penventinnie Lane, Truro, Cornwall, TR1 3LJ Page 15 of 16

A summary of the results will be published on the Trust s web site. Signed Date Page 16 of 16